O’Neil, Bert H.

The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity

Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature

Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways

Cited by 2,277

Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer: KEYNOTE-164

Le, D. T., Kim, T. W., Van Cutsem, E., Geva, R., Jäger, D., Hara, H., Burge, M., O’Neil, B., Kavan, P., Yoshino, T., et al. (2020) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer

Cited by 1,005

T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

Ott, P. A., Bang, Y.-J., Piha-Paul, S. A., Razak, A. R. A., Bennouna, J., Soria, J.-C., Rugo, H. S., Cohen, R. B., O’Neil, B. H., Mehnert, J. M., et al. (2019) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 969

Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers

Radovich, M., Kiel, P. J., Nance, S. M., Niland, E. E., Parsley, M. E., Ferguson, M. E., Jiang, G., Ammakkanavar, N. R., Einhorn, L. H., Cheng, L., et al. (2016) · Oncotarget

Cancer Genomics and DiagnosticsLung Cancer Treatments and Mutations

Cited by 111

Association of Coffee Intake with Survival in Patients With Advanced or Metastatic Colorectal Cancer

Mackintosh, C., Yuan, C., Ou, F.-S., Zhang, S., Niedzwiecki, D., Chang, I.-W., O’Neil, B. H., Mullen, B. C., Lenz, H.-J., Blanke, C. D., et al. (2020) · JAMA Oncology

Coffee research and impactsColorectal Cancer Treatments and Studies

Cited by 52

Whole recombinant Saccharomyces cerevisiae yeast expressing Ras mutations as treatment for patients with solid tumors bearing Ras mutations: Results from a phase 1 trial

Cohn, A., Morse, M. A., O’Neil, B., Whiting, S., Coeshott, C., Ferraro, J., Bellgrau, D., Apelian, D., & Rodell, T. C. (2018) · Journal of Immunotherapy

Immunotherapy and Immune ResponsesBacterial Cancer Therapy

Cited by 41

Evaluation of a locked nucleic acid form of antisense oligo targeting HIF-1α in advanced hepatocellular carcinoma

Wu, J., Contratto, M., Shanbhogue, K. P., Manji, G. A., O’Neil, B. H., Noonan, A., Tudor, R., & Lee, R. (2019) · World Journal of Clinical Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer, Hypoxia, and Metabolism

Cited by 41